Skip to main content
SpringerLink
Log in

Optimization of the Fine Particle Fraction of a Lyophilized Lysozyme Formulation for Dry Powder Inhalation

  • Research Paper
  • Published:
Pharmaceutical Research Aims and scope Submit manuscript

ABSTRACT

Purpose

A new dry powder inhalation technology creates inhalable particles from a coherent lyophilized bulk at the time of inhalation. The aim of this study was to evaluate several approaches to improve the fine particle fraction (FPF) and to understand underlying mechanisms.

Methods

Lysozyme was chosen as model drug. Phenylalanine and valine were added, and the freezing process was varied. Lyophilisate characteristics as well as aerosolization behavior was analyzed.

Results

The addition of the crystalline amino acids rendered a dose independent three-fold increase of the FPF. This is possibly due to enhanced fracture properties of the lyophilisates upon impact of the air stream and reduced particle agglomeration/cohesion caused by a rougher surface. This positive effect was well preserved over 3 months of storage. The structure of the lyophilisate was influenced by the freezing process which in turn affected the aerosolization behavior. Liquid nitrogen and vacuum-induced freezing performed best, doubling the FPF. The special cake morphology with elongated channels enabled easy disintegration. The resulting large porous particles comprise a low density being advantageous for a high FPF.

Conclusion

The variation of the lyophilization process and formulation utilizing excipients enabled an optimization of the FPF of the novel lyophilisate based DPI system.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6
Fig. 7
Fig. 8
Fig. 9
Fig. 10
Fig. 11
Fig. 12

Similar content being viewed by others

Abbreviations

ACI:

Andersen Cascade Impactor

API:

active pharmaceutical ingredient

DPI:

dry powder inhaler

ED:

emitted dose

FPF:

fine particle fraction

Lys:

lysozyme

MD:

metered dose

Phe:

L-phenylalanine

RH:

relative humidity

SEM:

scanning electron microscopy

Tg′:

glass transition temperature of the max. freeze concentrated solution

Val:

L-valine

XRD:

x-ray diffractometry

REFERENCES

  1. Newman SP, Busse WW. Evolution of dry powder inhaler design, formulation, and performance. Respir Med. 2002;96:293–304.

    Article  PubMed  CAS  Google Scholar 

  2. Frijlink HW, De Boer AH. Dry powder inhalers for pulmonary drug delivery. Expert Opin Drug Deliv. 2004;1:67–86.

    Article  PubMed  CAS  Google Scholar 

  3. Newhouse MT, Nantel NP, Chambers CB, Pratt B, Parry-Billings M. Clickhaler (a novel dry powder inhaler) provides similar bronchodilation to pressurized metered-dose inhaler, even at low flow rates. Chest. 1999;115:952–6.

    Article  PubMed  CAS  Google Scholar 

  4. Pitcairn GR, Lankinen T, Seppälä O-P, Newman SP. Pulmonary drug delivery from the Taifun dry powder inhaler is relatively independent of the patient’s inspiratory effort. J Aerosol Med. 2000;13:97–104.

    Article  PubMed  CAS  Google Scholar 

  5. Islam N, Gladki E. Dry powder inhalers (DPIs)—a review of device reliability and innovation. Int J Pharm. 2008;360:1–11.

    Article  PubMed  CAS  Google Scholar 

  6. Tobyn M, Staniforth JN, Morton D, Harmer Q, Newton ME. Active and intelligent inhaler device development. Int J Pharm. 2004;277:31–7.

    Article  PubMed  CAS  Google Scholar 

  7. Owens DR, Zinman B, Bolli G. Alternative routes of insulin delivery. Diabetic Med. 2003;20:886–98.

    Article  PubMed  CAS  Google Scholar 

  8. Chew NYK, Chan H-K. The role of particle properties in pharmaceutical powder inhalation formulations. J Aerosol Med. 2002;15:325–30.

    Article  PubMed  CAS  Google Scholar 

  9. Chow A, Tong H, Chattopadhyay P, Shekunov B. Particle engineering for pulmonary drug delivery. Pharm Res. 2007;24:411–37.

    Article  PubMed  CAS  Google Scholar 

  10. Yamashita C, Akagi A, Fukunaga Y. Dry powder inhalation system for transpulmonary administration, United States Patent 7735485 2010.

  11. Franks F. Freeze-drying of bioproducts: putting principles into practice. Eur J Pharm Biopharm. 1998;45:221–9.

    Article  PubMed  CAS  Google Scholar 

  12. Claus S, Schoenbrodt T, Weiler C, Friess W. Novel dry powder inhalation system based on dispersion of lyophilisates. Eur J Pharm Sci. 2011;43:32–40.

    Article  PubMed  CAS  Google Scholar 

  13. Hottot A, Vessot S, Andrieu J. Freeze drying of pharmaceuticals in vials: influence of freezing protocol and sample configuration on ice morphology and freeze-dried cake texture. Chem Eng Process. 2007;46:666–74.

    Article  CAS  Google Scholar 

  14. Liu J. Physical characterization of pharmaceutical formulations in frozen and freeze-dried solid states: techniques and applications in freeze-drying development. Pharm Dev Technol. 2006;11:3–28.

    Article  PubMed  CAS  Google Scholar 

  15. Kasper JC, Friess W. The freezing step in lyophilization: physico-chemical fundamentals, freezing methods and consequences on process performance and quality attributes of biopharmaceuticals. Eur J Pharm Biopharm. 2011;78:248–63.

    Article  PubMed  CAS  Google Scholar 

  16. Patapoff TW, Overcashier DE. The importance of freezing on lyophilization cycle development. BioPharm Int. 2002;72:16–21.

    Google Scholar 

  17. Searles JA, Carpenter JF, Randolph TW. The ice nucleation temperature determines the primary drying rate of lyophilization for samples frozen on a temperature-controlled shelf. J Pharm Sci. 2001;90:860–71.

    Article  PubMed  CAS  Google Scholar 

  18. Liu J, Viverette T, Virgin M, Anderson M, Dalal P. A study of the impact of freezing on the lyophilization of a concentrated formulation with a high fill depth. Pharm Dev Technol. 2005;10:261–72.

    PubMed  CAS  Google Scholar 

  19. Webb SD, Cleland JL, Carpenter JF, Randolph TW. Effects of annealing lyophilized and spray-lyophilized formulations of recombinant human interferon-γ. J Pharm Sci. 2003;92:715–29.

    Article  PubMed  CAS  Google Scholar 

  20. Ulubayram K, Eroglu I, Hasirci N. Gelatin microspheres and sponges for delivery of macromolecules. J Biomater Appl. 2002;16:227–41.

    Article  PubMed  CAS  Google Scholar 

  21. United States Pharmacopeia 36 Chapter 601—Physical tests and determinations: aerosols, nasal sprays, metered-dose inhalers, and dry powder inhalers, vol. 36. United States Pharmacopoial Convention Inc. 2012.

  22. Tang X, Pikal M. Design of freeze-drying processes for pharmaceuticals: practical advice. Pharm Res. 2004;21:191–200.

    Article  PubMed  CAS  Google Scholar 

  23. Pikal MJ, Shah S. Moisture transfer from stopper to product and resulting stability implications. Dev Biol Stand. 1992;74:165–77. discussion 177–169.

    PubMed  CAS  Google Scholar 

  24. Mattern M, Winter G, Kohnert U, Lee G. Formulation of proteins in vacuum-dried glasses. II. Process and storage stability in sugar-free amino acid systems. Pharm Dev Technol. 1999;4:199–208.

    Article  PubMed  CAS  Google Scholar 

  25. Akers MJ, Milton N, Byrn SR, Nail SL. Glycine crystallization during freezing: the effects of salt form, pH, and ionic strength. Pharm Res. 1995;12:1457–61.

    Article  PubMed  CAS  Google Scholar 

  26. Franks F, Auffret T. Freeze-drying of pharmaceuticals and biopharmaceuticals. Cambridge: RSC; 2007.

    Google Scholar 

  27. Chatterjee K, Shalaev EY, Suryanarayanan R. Partially crystalline systems in lyophilization: I Use of ternary state diagrams to determine extent of crystallization of bulking agent. J Pharm Sci. 2005;94:798–808.

    Article  PubMed  CAS  Google Scholar 

  28. Mohan R, Koo K-K, Strege C, Myerson AS. Effect of additives on the transformation behavior of l-phenylalanine in aqueous solution. Ind Eng Chem Res. 2001;40:6111–7.

    Article  CAS  Google Scholar 

  29. Roth C, Winter G, Lee G. Continuous measurement of drying rate of crystalline and amorphous systems during freeze-drying using an in situ microbalance technique. J Pharm Sci. 2001;90:1345–55.

    Article  PubMed  CAS  Google Scholar 

  30. French DL, Edwards DA, Niven RW. The influence of formulation on emission, deaggregation and deposition of dry powders for inhalation. J Aerosol Sci. 1996;27:769–83.

    Article  CAS  Google Scholar 

  31. Weiler C, Egen M, Trunk M, Langguth P. Force control and powder dispersibility of spray dried particles for inhalation. J Pharm Sci. 2010;99:303–16.

    Article  PubMed  CAS  Google Scholar 

  32. Stability Testing of New Drug Substances and Products Q1A(R2), International Confernece on Harmonisation of technical requirements for registration of pharmaceuticals for human use 2003.

  33. Kasper JC, Schaffert D, Ogris M, Wagner E, Friess W. Development of a lyophilized plasmid/LPEI polyplex formulation with long-term stability—a step closer from promising technology to application. J Control Release. 2011;151:246–55.

    Article  PubMed  CAS  Google Scholar 

  34. Roos Y, Karel M. Plasticizing effect of water on thermal behavior and crystallization of amorphous food models. J Food Sci. 1991;56:38–43.

    Article  CAS  Google Scholar 

  35. Searles JA. Freezing and annealing phenomena in lyophilization. In: Rey L, May JC, editors. Freeze-drying/lyophilization of pharmaceutical and biological products. New York: Marcel Dekker, Inc.; 2004.

    Google Scholar 

  36. Hsu CC, Nguyen HM, Yeung DA, Brooks DA, Koe GS, Bewley TA, et al. Surface denaturation at solid-void interface—a possible pathway by which opalescent participates form during the storage of lyophilized tissue-type plasminogen activator at high temperatures. Pharm Res. 1995;12:69–77.

    Article  PubMed  CAS  Google Scholar 

  37. Vanbever R, Mintzes JD, Wang J, Nice J, Chen D, Batycky R, et al. Formulation and physical characterization of large porous particles for inhalation. Pharm Res. 1999;16:1735–42.

    Article  PubMed  CAS  Google Scholar 

  38. Chang BS, Kendrick BS, Carpenter JF. Surface-induced denaturation of proteins during freezing and its inhibition by surfactants. J Pharm Sci. 1996;85:1325–30.

    Article  PubMed  CAS  Google Scholar 

Download references

ACKNOWLEDGMENTS AND DISCLOSURES

This research project is supported by Boehringer Ingelheim Pharma GmbH & Co. KG. We thank Holger Holakovsky and Gilbert Wuttke for the possibility to do the high speed camera recordings. We also thank Alexandra Pickel for her analytical contribution to this study.

Author information

Authors and Affiliations

  1. Department of Pharmacy, Pharmaceutical Technology & Biopharmaceutics, Ludwig-Maximilians-Universitaet Muenchen, Butenandtstr. 5, 81377, Munich, Germany

    Sarah Claus & Wolfgang Friess

  2. Boehringer Ingelheim Pharma GmbH & Co. KG, Binger Str. 173, 55216, Ingelheim am Rhein, Germany

    Claudius Weiler & Joerg Schiewe

Authors
  1. Sarah Claus
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Claudius Weiler
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Joerg Schiewe
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wolfgang Friess
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Wolfgang Friess.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Claus, S., Weiler, C., Schiewe, J. et al. Optimization of the Fine Particle Fraction of a Lyophilized Lysozyme Formulation for Dry Powder Inhalation. Pharm Res 30, 1698–1713 (2013). https://doi.org/10.1007/s11095-013-1015-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11095-013-1015-6

KEY WORDS

Search

Navigation